Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
Objectives: This study aimed to explore factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer (aNSCLC) patients treated with immune checkpoint inhibitors (ICIs). Methods: A total of 101 patients with aNSCLC receiving ICIs were included. The association bet...
Guardado en:
Autores principales: | Yahua Wu, Haishan Wu, Mingqiang Lin, Tianxiu Liu, Jiancheng Li |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e5b99e290dad40368c8d31d424deb3fc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy
por: Xiujing He, et al.
Publicado: (2021) -
A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
por: Yi-Dan Yan, et al.
Publicado: (2021) -
Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis
por: Nuttapong Ngamphaiboon, et al.
Publicado: (2021) -
Diagnosis and Management of Immunotherapy-related Liver Toxicity
por: HUA Yuwei, et al.
Publicado: (2021) -
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
por: Rosaria De Filippi, et al.
Publicado: (2021)